BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells

Cancer Letters

Volumn 365, Issue 2, 2015, Pages 190-200

  Yu, Jin Mei ^a   Sun, Wei ^a   Hua, Fang ^a   Xie, Jing ^a   Lin, Heng ^a   Zhou, Dan Dan ^a   Hu, Zhuo Wei ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

BCL6; Breast cancer; E cadherin; EMT; ZEB1

Indexed keywords

BCL6 INHIBITOR 79-6; BETA CATENIN; MESSENGER RNA; PROTEIN BCL 6; PROTEIN INHIBITOR; PROTEIN ZO1; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CTBP2; TRANSCRIPTION FACTOR DELTAEF1; TRANSCRIPTION FACTOR SIP1; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UVOMORULIN; BCL6 PROTEIN, HUMAN; CADHERIN; DNA BINDING PROTEIN; HOMEODOMAIN PROTEIN; SMALL INTERFERING RNA; ZEB1 PROTEIN, HUMAN;

ARTICLE; BCL6 GENE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MCF 7 CELL LINE; MDA 231 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; ZEB1 GENE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; CELL MOTION; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MCF-7 CELLS; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84937641581     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.05.029     Document Type: Article

References (49)

1. Ci W., Polo J.M., Melnick A. B-cell lymphoma6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Curr. Opin. Hematol 2008, 15:381-390.
2. Staudt L.M., Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol 2005, 87:163-208.
3. Logarajah S., Hunter P., Kraman M., Steele D., Lakhani S., Bobrow L., et al. BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene 2003, 22:5572-5578.
4. Bos R., van Diest P.J., van der Groep P., Greijer A.E., Hermsen M.A., Heijnen I., et al. Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D1 and hypoxia-inducible factor-1alpha (HIF-1alpha). Oncogene 2003, 22:8948-8951.
5. Wu Q., Liu X., Yan H., He Y.-H., Ye S., Cheng X.W., et al. B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells. BMC Cancer 2014, 418:1471-2407.
6. Walker S.R., Liu S., Xiang M., Nicolais M., Hatzi K., et al. The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene 2015, 34:1073-1082.
7. Baron B.W., Anastasi J., Montag A., Huo D., Baron R.M., Karrison T., et al. The human BCL6 transgene promotes the development of lymphomas in the mouse. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14198-14203.
8. Ahmad K.F., Melnick A., Lax S., Bouchard D., Liu J., Kiang C.L., et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol. Cell 2003, 12:1551-1564.
9. Cerchietti L.C., Ghetu A.F., Zhu X., Da Silva G.F., Zhong S., Matthews M., et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010, 17:400-411.
10. Cerchietti L.C., Yang S.N., Shaknovich R., Hatzi K., Polo J.M., Chadburn A., et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009, 113:3397-3405.
11. Fujita N., Jaye D.L., Geigerman C., Akyildiz A., Mooney M.R., Boss J.M., et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 2004, 119:75-86.
12. Mendez L.M., Polo J.M., Yu J.J., Krupski M., Ding B.B., Melnick A., et al. CtBP is an essential corepressor for BCL6 autoregulation. Mol. Cell. Biol 2008, 28:2175-2186.
13. Bronsert P., Enderle-Ammour K., Bader M., Timme S., Kuehs M., Csanadi A., et al. Cancer cell invasion and EMT marker expression: a three-dimensional study of the human cancer-host interface. J. Pathol 2014, 234:410-422.
14. Na D.C., Lee J.E., Yoo J.E., Oh B.K., Choi G.H., Park Y.N. Invasion and EMT-associated genes are up-regulated in B viral hepatocellular carcinoma with high expression of CD133-human and cell culture study. Exp. Mol. Pathol 2011, 90:66-73.
15. Ansieau S. EMT in breast cancer stem cell generation. Cancer Lett 2013, 338:63-68.
16. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest 2009, 119:1429-1437.
17. Kokkinos M.I., Wafai R., Wong M.K., Newgreen D.F., Thompson E.W., Waltham M. Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 2007, 185:191-203.
18. Dong C., Wu Y., Wang Y., Wang C., Kang T., Rychahou P.G., et al. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 2013, 32:1351-1362.
19. Ye Y., Xiao Y., Wang W., Yearsley K., Gao J.X., Shetuni B., et al. ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 2010, 29:1451-1462.
20. Papadopoulou V., Postigo A., Sanchez-Tillo E., Porter A.C., Wagner S.D. ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus. Biochem. J. 2010, 427:541-550.
21. Xu R., Zhang Y., Gu L., Zheng J., Cui J., Dong J., et al. Arf6 regulates EGF-induced internalization of E-cadherin in breast cancer cells. Cancer Cell Int 2015, 15:11.
22. Lee S., Hong S., Kim S., Kang S. Ataxin-1 occupies the promoter region of E-cadherin in vivo and activates CtBP2-repressed promoter. Biochim. Biophys. Acta 2011, 1813:713-722.
23. Lander R., Nasr T., Ochoa S.D., Nordin K., Prasad M.S., Labonne C. Interactions between Twist and other core epithelial-mesenchymal transition factors are controlled by GSK3-mediated phosphorylation. Nat. Commun 2013, 4:1542.
24. Hua F., Mu R., Liu J., Xue J., Wang Z., Lin H., et al. TRB3 interacts with SMAD3 promoting tumor cell migration and invasion. J. Cell Sci 2011, 124:3235-3246.
25. Yang H.Z., Cui B., Liu H.Z., Mi S., Yan J., Yan H.M., et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS ONE 2009, 4:e6520.
26. Poehlsgaard J., Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol 2005, 3:870-881.
27. Obrig T.G., Culp W.J., McKeehan W.L., Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J. Biol. Chem 1971, 246:174-181.
28. Lv Q., Wang W., Xue J., Hua F., Mu R., Lin H., et al. DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res 2012, 72:3238-3250.
29. Cervoni N., Szyf M. Demethylase activity is directed by histone acetylation. J. Biol. Chem 2001, 276:40778-40787.
30. Kouskouti A., Talianidis I. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J. 2005, 24:347-357.
31. Kang Y., Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118:277-279.
32. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
33. Yilmaz M., Christofori G., Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol. Med 2007, 13:535-541.
34. Sarrió D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997.
35. Singhai R., Patil V.W., Jaiswal S.R., Patil S.D., Tayade M.B., Patil A.V. E-Cadherin as a diagnostic biomarker in breast cancer. N. Am. J. Med. Sci 2011, 3:227-233.
36. Collu G.M., Brennan K. Cooperation between Wnt and Notch signalling in human breast cancer. Breast Cancer Res 2007, 9:105.
37. Leong K.G., Niessen K., Kulic I., Raouf A., Eaves C., Pollet I., et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J. Exp. Med 2007, 204:2935-2948.
38. Wu Y., Deng J., Rychahou P.G., Qiu S., Evers B.M., Zhou B.P. Stabilization of snail by NF-kappa B is required for inflammation-induced cell migration and invasion. Cancer Cell 2009, 15:416-428.
39. Chen J., Imanaka N., Chen J., Griffin J.D. Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br. J. Cancer 2010, 102:351-360.
40. Avtanski D.B., Nagalingam A., Bonner M.Y., Arbiser J.L., Saxena N.K., Sharma D. Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis. Mol. Oncol 2014, 8:565-580.
41. Rafael D., Doktorovová S., Florindo H.F., Gener P., Abasolo I., Schwartz S., et al. EMT blockage strategies: targeting akt dependent mechanisms for breast cancer metastatic behaviour modulation. Curr. Gene Ther 2015, 15:300-312.
42. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
43. Bracken C.P., Gregory P.A., Kolesnikoff N., Bert A.G., Wang J., Shannon M.F., et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchyma transition. Cancer Res 2008, 68:7846-7854.
44. Comijn J., Berx G., Vermassen P., Verschueren K., van Grunsven L., Bruyneel E., et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 2001, 7:1267-1278.
45. Dave N., Guaita-Esteruelas S., Gutarra S., Frias A., Beltran M., Peiro S., et al. Functional cooperation between Snail1 and Twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition. J. Biol. Chem 2011, 286:12024-12032.
46. Gemmill R.M., Roche J., Potiron V.A., Nasarre P., Mitas M., Coldren C.D., et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2011, 300:66-78.
47. Ono H., Imoto I., Kozaki K., Tsuda H., Matsui T., Kurasawa Y., et al. SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. Oncogene 2012, 31:4923-4934.
48. Drake J.M., Barnes J.M., Madsen J.M., Domann F.E., Stipp C.S., Henry M.D. ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells. J. Biol. Chem 2010, 285:33940-33948.
49. Chaffer C.L., Marjanovic N.D., Lee T., Bell G., Kleer C.G., Reinhardt F., et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154:61-74.